PCT Ltd (PCTL)

[Long term]

DD & links & for CANADA Consolidated
ACTION NEEDEDPctl has been trying to get in contact with the government to make them aware of our machine & what it can do
We can help with & in our numbers send them copies of the DD that’s been posted

This is the contact point in government that needs to know about pctl Paradigm Convergence Technology. (Read below)

https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/


See how it works - https://lnkd.in/eacqr7x

My VP of nyc hospital attests to how good our machine works

https://www.linkedin.com/search/results/content/?facetSortBy=date_posted&keywords=Jonathan%20Johonnesson&origin=GLOBAL_SEARCH_HEADER


Info they’ll need:
PODCAST LINK click
Click in search....Pctl

This is who we can contact in government to make them aware of our machine.

point of entry for the submission of market research packages and meeting requests from interested stakeholders.
The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.
At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development.  Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed.
Ideal technologies and products would (but are not required to) be:
* - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging .Infectious Disease rapid response capabilities
* - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
* - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)
 
Would you like to meet with a federal agency regarding a product that you are developing for COVID-19?
If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information.

Select A portion of this DD ( below dotted line)& send to government site
https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/

PR/heightened demand: https://www.businesswire.com/news/home/20200313005307/en/

Annihilyzer™ system: https://www.youtube.com/watch?v=bZLjJdqpz9s&feature=youtu.be

Paradigm Convergence Technologies Corporation
Summarized Due Diligence Sheet for Investing
[color=red]

ACTION NEEDEDPctl has been trying to get in contact with the government to make them aware of our machine & what it can do
We can help with & in our numbers send them copies of the DD that’s been


This is the contact point in government that needs to know about pctl Paradigm Convergence Technology. (Read below)

https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/



Info they’ll need:

PODCAST LINK click
Click in search....Pctl


Much more DD below dotted line

This is who we can contact in government to make them aware of our machine.

point of entry for the submission of market research packages and meeting requests from interested stakeholders.
The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.
At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed.
Ideal technologies and products would (but are not required to) be:
* - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging .Infectious Disease rapid response capabilities
* - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
* - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)

Would you like to meet with a federal agency regarding a product that you are developing for COVID-19?
If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information.

===================================================

DD




--GENERAL INFORMATION---

Company Site: para-con.com
Twitter: @PCTL2020
Investor Relations Chesapeake Group - Get on the email list for news [e-mail]

About: a technology licensing company specializing in environmentally safe solutions for global sustainability with products for various markets they serve.

Mission: Infectious Disease and Contamination Control

Markets Served: Hospitals & Healthcare, Agriculture, Oil & Gas, Hotel & Tourism, Food Service/Production

About Products: Products and solutions are designed to take an environmentally conscious approach to combating the spread of infectious disease in the Healthcare and Cleaning industries, as well as contributing to the sustainability of global natural resources in the energy and agriculture markets.

The PCT Annihilyzer® Patented Monitoring, Tracking & Reporting System
The Kiosk, which sits on top of the Filling Station Cabinet, houses The PCT Annihilyzer® System’s computer controls, information system, RFID tagging and reading system and an interactive touch screen display.


---FINANCIAL INFO---

Filings: LINK

Current info as of 3/9/20
Authorized- 1,000,000,000
Outstanding- 511,315,300
Restricted- 35,139,690

Standard Registrar and Transfer Company
440 East 400 South, Suite 200
Salt Lake City, UT 84111
Phone: [phone] or 801-596-2150
www.standardtransferco.com
Amy Merrill Email: [e-mail]


---CURRENT CLIENT LIST---

1: Morgan Stanley Presbyterian Children’s Hospital.
(3959 Broadway At, W 165 St, New York NY 10032)

2: Mount Sinai South Nassau Hospital
(1 Healthy Way, Oceanside NY 11572)

3: Carson Tahoe Regional Medical Center
(1600 Medical Pkwy, Carson City NV 89703)

4: SUNY Downstate Medical Center
(450 Clarkson Ave, Brooklyn NY 11203)

5: Johnston UNC Healthcare Hospital Smithfield
(509 N Brightleaf Blvd , Smithfield, NC 27577)

6: Memorial Sloan Kettering Cancer Center ??? Maybe
(1275 York Avenue New York, NY 10065)

7: North Tees and Hartlepool NHS Foundation Trust, (UK Trial underway began Jan 15th 2020 - 60 day trial)
(University Hospital of Hartlepool, Holdforth Road, Hartlepool, TS24 9AH)
(University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE)

8: New York Presbyterian Columbia Hospital
(Ranked Top 5 in the Nation)
(622 W 168th St, New York NY 10032)
---VP recently endorsed in a LinkedIn post---

9: New York Hospital -- as per PR Release (labeled #1 below)



---PR & RELATED INFORMATION---


1. 03/11/20 - PCT LTD Experiencing Rapid Increase in Interest and Receives Purchase Order from Additional Hospital in New York City PR LINK

2. 03/09/20 - Interview: PCT LTD Hospital Infection Control System installed in seven hospitals and expanding INTERVIEW LINK

3. 02/14/20 - PCT LTD Schedules Investor Call (Call took place on 2/20/20) PR LINK Audio Link (Written Summation below)

4. 01/30/20 - PCT LTD Executes Term Sheet for Debt Financing PR LINK

5. 01/08/20 - PCT LTD Discusses Their International Expansion and Growth Strategy with The Stock Day Podcast PR LINK

6. 12/16/19 - PCT LTD Issues Company Update and Signs Collaborative Agreement for Oil & Gas, and Cannabis Applications PR LINK

7. 10/31/19 - PCT LTD Continues to Expand By Signing Agreement with SUNY Downstate Medical Center Worth over $500,000 PR LINK

8. 10/25/19 - 3rd Quarter 8K released (see above FILINGS link)

9. 10/22/19 - Hospital-acquired Infection Control Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast Period MARKET RESEARCH PR

10. 10/22/19 - PCT LTD Deploys Initial Annihilyzer(R) Infection Control System to the United Kingdom PR LINK

11. 10/4/19 - PCT LTD Announces Additional Hospital Installation of Annihilyzer(R) Infection Control System PR LINK

12. 7/26/19 - The Infection Prevention Strategy is pleased to announce our Top Innovations of the Year: 2019 (Annihilyzer) PR LINK

13. 5/6/2019 - PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems (A TOP 5 hospital in the U.S. AND --#1 in NY-- CONVERTED from Trial to a customer AFTER a successful trial period) - Morgan Stanley Presbyterian Children’s Hospital PR LINK

14. 2/25/19 - PCT LTD Installs a Large Volume Hydrolyte® System with Option Agreement for 4 additional LVH Systems with Oil & Gas Industry Customer PR LINK

15. 1/10/19 - PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center PR LINK

16. 11/08/18 - PCT LTD Announces Completion of Major Commercialization Milestones and Promotion of Jody Read to CEO Position PR LINK

17. 5/16/18 - Newly Launched Disinfecting System Reduces Hospital Acquired Infections PR LINK

18. 5/10/18 - PCT LTD Receives Patents for RFID Tracking Technology in Cleaning System (US Patent#9679170) PR LINK



----Investor Call Summation, Paradigm Convergeance Technologies Corporation----
---First 10 minutes of call---

---Addressing Financial Filings---

3rd Quarter 10Q
In final review with auditors & SEC Attorneys
Expected to be completed in up to 3 weeks
(updated per IR email--- expected in the next week)

10K
Expected to be filed by April 13th

Convertible Notes
"very active negotiations" to come to a resolve by time of 10K filing (April 13th)

No material change is O/S in months

very actively negotiating financing with negligible, if any, dissolution
No anticipation of R/S

---Growth of about 400% in 2019---
on target to grow exponentially in 2020

G&A down significantly
company become more efficicent, losses narrowed significantly down around 75% from 2018

---Currently Doing---

PCT UK joint venture partner
Trial ongoing: Universities as well as hospitals involved to verify U.S. results
"unless bacteria and virsuses are any different, which they aren't, don't anticipate any difficulty verifying claims"

"Preliminary discussions between PCT UK and National Healthcare system of the UK"

---Markets---
Primary Focus on healthcare sector - hospitals, medical centers assisted living, rehab facilities

Secondarily - Oil & Gas, remidiation of Hydrogen Sulfide (very poisonous, corrosive, and flammable)

Recently - Cannabis Industry - purveyor of service
"Happy to discover our product greatly mitigates or totally elimiants the 3 major problems they are having"

---Current Placement--- (Does not include newest NY Hospital announced above in PR on 3/11/20)
8 hospitals, 11 units installed with "3 more slated in next few weeks with more behind it"


Endorsement from VP of MY Presbyterian
[Suppressed Image]




Not sure how many are aware of BARDA, but I came across a post on Twitter this evening and after doing a little digging, found this:

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).

In my eyes that's most certainly an organization that should be aware of the Annihilyzer product, so I connected with their Director, Rick B and provided a post on Linkedin for more exposure to their request of building out a comprehensive portfolio of COVID-19 countermeasures. See below.

(For my privacy, I did redact my information on the image)

Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services

[Suppressed Image]

Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services


UPDATED DUE DILIGENCE 3-17 - RESEARCH NOW
Below is a good portion of the DD done here, by myself and others. Do YOURS now!
(Also pinned on top of board)

Paradigm Convergence Technologies Corporation
Summarized Due Diligence Sheet for Investing


---GENERAL INFORMATION---

Company Site: para-con.com
Twitter: @PCTL2020 - (I urge you to follow them and review their posts)
Investor Relations Chesapeake Group - Get on the email list for news [e-mail]

About: a technology licensing company specializing in environmentally safe solutions for global sustainability with products for various markets they serve.

Mission: Infectious Disease and Contamination Control

Markets Served: Hospitals & Healthcare, Agriculture, Oil & Gas, Hotel & Tourism, Food Service/Production

About Products: Products and solutions are designed to take an environmentally conscious approach to combating the spread of infectious disease in the Healthcare and Cleaning industries, as well as contributing to the sustainability of global natural resources in the energy and agriculture markets.

The PCT Annihilyzer® Patented Monitoring, Tracking & Reporting System
The Kiosk, which sits on top of the Filling Station Cabinet, houses The PCT Annihilyzer® System’s computer controls, information system, RFID tagging and reading system and an interactive touch screen display.


---FINANCIAL INFO---

Filings: LINK

Current info as of 3/9/20
Authorized- 1,000,000,000
Outstanding- 511,315,300
Restricted- 35,139,690

Standard Registrar and Transfer Company
440 East 400 South, Suite 200
Salt Lake City, UT 84111
Phone: [phone] or 801-596-2150
www.standardtransferco.com
Amy Merrill Email: [e-mail]


---CURRENT CLIENT LIST---

1: Morgan Stanley Presbyterian Children’s Hospital.
(3959 Broadway At, W 165 St, New York NY 10032)

2: Mount Sinai South Nassau Hospital
(1 Healthy Way, Oceanside NY 11572)

3: Carson Tahoe Regional Medical Center
(1600 Medical Pkwy, Carson City NV 89703)

4: SUNY Downstate Medical Center
(450 Clarkson Ave, Brooklyn NY 11203)

5: Johnston UNC Healthcare Hospital Smithfield
(509 N Brightleaf Blvd , Smithfield, NC 27577)

6: Memorial Sloan Kettering Cancer Center ??? Maybe
(1275 York Avenue New York, NY 10065)

7: North Tees and Hartlepool NHS Foundation Trust, (UK Trial underway began Jan 15th 2020 - 60 day trial)
(University Hospital of Hartlepool, Holdforth Road, Hartlepool, TS24 9AH)
(University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE)

8: New York Presbyterian Columbia Hospital
(Ranked Top 5 in the Nation)
(622 W 168th St, New York NY 10032)
---VP recently endorsed in a LinkedIn post---

9: New York Hospital -- as per PR Release (labeled #1 below)


---PR & RELATED INFORMATION---

1. 03/18/20 - PCT LTD Receives Large Purchase Order for Recurring Sales of Fluids for Non-Medical Use and Explains Current Revenue Streams PR LINK

2. 03/16/20 - PCT LTD Interview with Stock Day Podcast (MUST LISTEN) PR LINK

3. 03/13/20 - PCT LTD Adds International Distributor and Sells High-Volume Equipment to Existing Customer as a Result of Heightened Demand PR LINK

4. 03/11/20 - PCT LTD Experiencing Rapid Increase in Interest and Receives Purchase Order from Additional Hospital in New York City PR LINK

5. 03/09/20 - Interview: PCT LTD Hospital Infection Control System installed in seven hospitals and expanding INTERVIEW LINK

6. 02/14/20 - PCT LTD Schedules Investor Call (Call took place on 2/20/20) PR LINK Audio Link (Written Summation below)

7. 01/30/20 - PCT LTD Executes Term Sheet for Debt Financing PR LINK

8. 01/08/20 - PCT LTD Discusses Their International Expansion and Growth Strategy with The Stock Day Podcast PR LINK

9. 12/16/19 - PCT LTD Issues Company Update and Signs Collaborative Agreement for Oil & Gas, and Cannabis Applications PR LINK

10. 10/31/19 - PCT LTD Continues to Expand By Signing Agreement with SUNY Downstate Medical Center Worth over $500,000 PR LINK

11. 10/25/19 - 3rd Quarter 8K released (see above FILINGS link)

12. 10/22/19 - Hospital-acquired Infection Control Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast Period MARKET RESEARCH PR

13. 10/22/19 - PCT LTD Deploys Initial Annihilyzer(R) Infection Control System to the United Kingdom PR LINK

14. 10/4/19 - PCT LTD Announces Additional Hospital Installation of Annihilyzer(R) Infection Control System PR LINK

15. 7/26/19 - The Infection Prevention Strategy is pleased to announce our Top Innovations of the Year: 2019 (Annihilyzer) PR LINK

16. 5/6/2019 - PCT LTD Announces New Purchase Order as the Result of a Successful Trial of Annihilyzer® Infection Control Systems (A TOP 5 hospital in the U.S. AND --#1 in NY-- CONVERTED from Trial to a customer AFTER a successful trial period) - Morgan Stanley Presbyterian Children’s Hospital PR LINK

17. 2/25/19 - PCT LTD Installs a Large Volume Hydrolyte® System with Option Agreement for 4 additional LVH Systems with Oil & Gas Industry Customer PR LINK

18. 1/10/19 - PCT LTD Executes New Master Service Agreement for Installation of Annihilyzer® Hospital Infection Control System at Carson Tahoe Regional Medical Center PR LINK

19. 11/08/18 - PCT LTD Announces Completion of Major Commercialization Milestones and Promotion of Jody Read to CEO Position PR LINK

20. 5/16/18 - Newly Launched Disinfecting System Reduces Hospital Acquired Infections PR LINK

21. 5/10/18 - PCT LTD Receives Patents for RFID Tracking Technology in Cleaning System (US Patent#9679170) PR LINK



----Investor Call Summation, Paradigm Convergeance Technologies Corporation----
---First 10 minutes of call---

---Addressing Financial Filings---

3rd Quarter 10Q
In final review with auditors & SEC Attorneys
Expected to be completed in up to 3 weeks
(updated per IR email--- expected in the next week)

10K
Expected to be filed by April 13th

Convertible Notes
"very active negotiations" to come to a resolve by time of 10K filing (April 13th)

No material change is O/S in months

very actively negotiating financing with negligible, if any, dissolution
No anticipation of R/S

---Growth of about 400% in 2019---
on target to grow exponentially in 2020

G&A down significantly
company become more efficicent, losses narrowed significantly down around 75% from 2018

---Currently Doing---

PCT UK joint venture partner
Trial ongoing: Universities as well as hospitals involved to verify U.S. results
"unless bacteria and virsuses are any different, which they aren't, don't anticipate any difficulty verifying claims"

"Preliminary discussions between PCT UK and National Healthcare system of the UK"

---Markets---
Primary Focus on healthcare sector - hospitals, medical centers assisted living, rehab facilities

Secondarily - Oil & Gas, remidiation of Hydrogen Sulfide (very poisonous, corrosive, and flammable)

Recently - Cannabis Industry - purveyor of service
"Happy to discover our product greatly mitigates or totally elimiants the 3 major problems they are having"

---Current Placement--- (Does not include newest NY Hospital announced above in PR on 3/11/20)
8 hospitals, 11 units installed with "3 more slated in next few weeks with more behind it"


Endorsement from VP of MY Presbyterian and other execs
[Suppressed Image]

[Suppressed Image]

[Suppressed Image]

[Suppressed Image]


Not sure how many are aware of BARDA, but I came across a post on Twitter this evening and after doing a little digging, found this:

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).

In my eyes that's most certainly an organization that should be aware of the Annihilyzer product, so I connected with their Director, Rick B and provided a post on Linkedin for more exposure to their request of building out a comprehensive portfolio of COVID-19 countermeasures. See below.

(For my privacy, I did redact my information on the image)

Post made to BARDA Director, Deputy Assistant Secretary for Preparedness & Response - U.S. Department of Health & Human Services

=================
exactly what the EPA said

Quote:

List N includes products that meet EPA’s criteria for use against SARS-CoV-2, the novel coronavirus that causes the disease COVID-19.



The key word here is against The EPA does not come out and say any products on these lists will kill CV-19. However I doubt the EPA would use a strong word as against in the above statement.

Quote:

Note: Inclusion on this list does not constitute an endorsement by EPA. There may be additional disinfectants that meet the criteria for use against SARS-CoV-2. EPA will update this list with additional products as needed.



It's pretty obvious this disclaimer is stating the EPA does not endorse as in recommend any product that's listed. They do not because it would constitute marketing for that product.... The EPA also recognizes that there are other products that meet the criteria against SARS-CV-2 AKA Coronavirus. Why do they make this statement? Because there are other products that are registered with the EPA that are not on this list that meets the criteria against CV-19

Nothing hard to understand there. Here is the a pic of it below:

[Suppressed Image]


Lets move on

List N: Disinfectants for Use Against SARS-CoV-2 | Pesticide ...www.epa.gov › pesticide-registration › list-n-disinfectants-use-against-...
If a product qualified for the Emerging Viral Pathogen Claim, it demonstrated efficacy against a harder-to-kill virus than the enveloped human coronavirus

From this statement we know that EXCELYTE which meets this criteria. How do we know this? We know because they are on the N list under EPA registration 92108-1. I also believe this Reg number can be used against the harder to lill Norovirus. Coronavirus is easier to kill than Norovirus. Any amount of basic DD will show that.

Below is the reg and product number for EXCELYTE
[Suppressed Image]

Finally Below is the EPA reg link for EXCELYTE showing it's registered to PCT Ltd. This link is the original registration.

https://iaspub.epa.gov/apex/pesticides/f?p=PPLS:8:1272595636521::NO::P8_PUID,P8_RINUM:513158,92108-1


To wrap it all up is the link to the current N list


https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2


Pretty basic stuff is you ask me lol

============
PCT LTD Obtains EPA Approval for Emerging Pathogens Labeling for Use Against SARS-CoV-2, the Novel Coronavirus That Causes the Disease COVID-19
Business WireMarch 27, 2020, 9:49 AM CST

PCT LTD (OTC Pink: PCTL) ("PCTL") is pleased to announce that it has received approval for "emerging pathogens" labeling with the US EPA.

The application was filed under the guidance document "Guidance to Registrants: Process for Making Claims Against Emerging Viral Pathogens Not on EPA-Registered Disinfectant Labels." It was approved on March 26th, 2020. The guidance document provides the following information regarding different classes of viruses and their resistance to being killed by disinfectants:

EPA and the Centers for Disease Control and Prevention (CDC) recognize that certain microorganisms can be ranked with respect to their tolerance to chemical disinfectants. The Spaulding Classification model, used by CDC, tiers microorganisms in accordance with the level of resistance to being killed (inactivation) by typical disinfectant products. With this approach viruses are divided into three viral subgroups (small non-enveloped, large non-enveloped, and enveloped) based on their relative resistance to inactivation … According to this hierarchy, if an antimicrobial product can kill a small, non-enveloped virus it should be able to kill any large, non-enveloped virus or any enveloped virus. Similarly, a product that can kill a large, non-enveloped virus should be able to kill any enveloped virus.


Small, Non-Enveloped Viruses (<50 nm): These small, non-enveloped viruses can be highly resistant to inactivation by disinfection. Despite the lack of a lipid envelope, these organisms have a very resistant protein capsid…

Large, Non-Enveloped Viruses: Compared to small, non-enveloped viruses, these viruses are less resistant to inactivation by disinfection. Although they have a resistant protein capsid, their larger size (50-100nm) makes them more vulnerable than their smaller viral counterparts…

Enveloped Viruses: Enveloped viruses are the least resistant to inactivation by disinfection. The structure of these viruses includes a lipid envelope, which is easily compromised by most disinfectants. Once the lipid envelope is damaged, the integrity of the virus is compromised, thereby neutralizing its infectivity.

In addition to being "an EPA-registered, hospital/healthcare or broad-spectrum disinfectant …", in order to meet product eligibility criteria, the product "should have disinfectant efficacy claims against at least one of the following viral pathogen groupings:

a) A product should be approved by EPA to inactivate at least one large or one small non-enveloped virus to be eligible for use against an enveloped emerging viral pathogen.

b) A product should be approved by EPA to inactivate at least one small, non-enveloped virus to be eligible for use against a large, non-enveloped emerging viral pathogen.

c) A product should be approved by EPA to inactivate at least two small, non-enveloped viruses with each from a different viral family to be eligible for use against a small, non-enveloped emerging viral pathogen.

This approach, where disinfectant products registered for use against viral pathogens in one category of the Spaulding Classification model can be presumed effective against viral pathogens in less-resistant categories, is intended to serve as a conservative approach to identifying disinfectant products likely to be effective against emerging pathogens."

As a result of meeting all of the Product Eligibility Criteria, PCT LTD can now make the following statement "only through the following communication outlets: … "1-800" consumer information services, social media sites and company websites (non-label related) … [as well as] technical literature distributed exclusively to health care facilities, physicians, nurses and public health officials":

This Product meets the criteria to make claims against certain emerging viral pathogens from the following viral category[ies]:

Enveloped Viruses

Large Non-Enveloped Viruses

Small Non-Enveloped Viruses


For an emerging viral pathogen that is a/an…
…follow the directions for use for the following organisms on the label:
Enveloped virus
Norovirus
Large, non-enveloped virus
Norovirus
Small, non-enveloped virus
Norovirus, Rhinovirus (Type 16)

Hydrolyte® has demonstrated effectiveness against viruses similar to SARS-CoV-2 virus on hard, non-porous surfaces. Therefore, Hydrolyte® can be used against SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/community/home/cleaning-disinfection.html for additional information.

COVID-19 is caused by SARS-CoV-2 virus. Hydrolyte® kills similar viruses and therefore can be used against SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/community/home/cleaning-disinfection.html for additional information.

"We are very pleased to receive approval for an "emerging pathogens" claim on our product label," says CEO Gary Grieco. "It represents an important step for us as a business and in helping to control the spread of infectious disease as a whole. Additionally, we are now prequalified for future emerging pathogens of any virus classification."

Due to the ongoing coronavirus pandemic, PCT LTD has seen an increased number of inquiries from existing clients, sub-registrants, and distributors; in addition to new and prospective customers. The company recently announced that they had temporarily shifted their focus towards producing mass quantities of disinfecting fluids to meet growing demand.

"Fluid sales have been tremendous for us," says PCT Ltd CEO Gary Grieco. "To put it simply, we are routinely shipping fluids out at rapid pace and into the hands of trained professionals where our product can be put to good use fighting the spread of infectious disease in our communities. We are limited only by our capacity to produce the fluids, but we expect to double our production capacity by April 1st."

Additional News and Corporate Updates:

PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL.

About PCT LTD:

PCT LTD ("PCTL") focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting, cleaning and tracking technologies. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, "PCTL" aspires to and is actively engaged in preparations for up-listing its common stock to a national securities exchange. The Company established entry into its target markets with commercially viable products in the United States and now continues to gain market share in the U.S. and U.K.

Forward-Looking Statements:

This press release contains "forward-looking statements" as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."

Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: the impact of having met the EPA Criteria for use Against SARS-CoV-2, actual sales derived by the Company; the transition to producing large quantities of fluids; PCTL's and its subsidiary's business prospects; PCTL's ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCTL to execute its business plan; any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements PCTL makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the SEC. PCTL undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005363/en/

Contacts

Gary Grieco, CEO and Chairman, PCT LTD
[phone] Office
[phone] Fax
www.para-con.com
www.pctcorphealth.com
www.survivalyte.com

Brokers and Analysts: Chesapeake Group
[phone]
[e-mail]
==================================================================================================================. CANADA INFO & LINKS
BokehRebl  
Tuesday, 03/31/20 10:29:25 PM
Re: Long term post# 78282
?
0
Post # 78283 of 78339 

Here’s THE list I put together of all relevant contact in the US and Canadien Government, Feel free to add more!

USA Counter Measures
https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/

Canada calling all suppliers
https://buyandsell.gc.ca/calling-all-suppliers-help-canada-combat-covid-19


Health ministers of Canada
Patty Hardy
[e-mail]

————————————————

Health minister of Quebec
Danielle McCann
[e-mail]
[e-mail]

Health minister of Ontario
Christine Elliott
[e-mail]

Health minister of British Columbia
Adrian Dix
[e-mail]

Health Minister of Alberta
Tyler Shandro
[e-mail]
Jason Luan
[e-mail]

Health Minister of Saskatchewan
Jim Reiter
[e-mail]

Health Minister of Manitoba
Cameron Frysien
[e-mail]

Others for Canada

Chief Public Health Officer of Canada
Twitter @CPHO_Canada
Dr. Theresa Tam

[e-mail]
[e-mail]
general email


Health Commissioners USA


Alabama
Scott Harris, MD, MPH [Bio]
State Health Officer
[e-mail]

Alaska
Anne Zink, MD, FACEP*
Chief Medical Officer
[e-mail]

Arizona
Cara M. Christ, MD, MS [Bio]
Director and State Health Official
[e-mail]

Arkansas
Nathaniel H. Smith, MD, MPH [Bio]
Director and State Health Officer
[e-mail]

California
Sonia Angell, MD, MPH
Director, Department of Public Health
[e-mail]

Colorado
Jill Ryan, MPH [Bio]
Executive Director
[e-mail]

Commonwealth of Northern Mariana Islands
Esther L. Muña, MHA, FACHE [Bio]
CEO, Commonwealth Healthcare Corporation
[e-mail]

Connecticut
Renee Coleman-Mitchell, MPH [Bio]
Commissioner\
[e-mail]


Delaware
Karyl Rattay, MD, MS [Bio]
Director, Division of Public Health
[e-mail]


District of Columbia
LaQuandra S. Nesbitt, MD, MPH [Bio]
Director
[e-mail]

Florida
Scott Rivkees, MD
State Surgeon General
[e-mail]
[e-mail]

Georgia
Kathleen Toomey, MD, MPH [Bio]
Commissioner, Director of Health Protection
[e-mail]

Guam
Linda Unpingco-DeNorcey, MPH [Bio]
Director, Department of Public Health and Social Services
[e-mail]

Hawaii
Bruce S. Anderson, PhD [Bio]
Director of Health
[e-mail]

Idaho
Elke Shaw-Tulloch, MHS [Bio]
Public Health Administrator
[e-mail]

Illinois
Ngozi Ezike, MD [Bio]
Director of Public Health
[e-mail]

Indiana
Kristina M. Box, MD [Bio]
State Health Commissioner
[e-mail]

Iowa
Gerd W. Clabaugh, MPA [Bio]
Director
[e-mail]

Kansas
Lee Norman, MD, MHS, MBA*
Secretary
[e-mail]

Kentucky
Angela Dearinger, MD, MPH*
Commissioner
[e-mail]

Louisiana
Alexander Billioux, MD, DPhil [Bio]
Assistant Secretary of Health
[e-mail]

Maine
Nirav Shah, MD, JD*
Director, Maine Center for Disease Control and Prevention
[e-mail]

Maryland
Robert Neall
Secretary of Health
Frances B. Phillips, RN, MHA [Bio]
Deputy Secretary for Public Health Services
S/THO Designee
[e-mail]

Massachusetts
Monica Bharel, MD, MPH [Bio]
Commissioner
[e-mail]

Michigan
Joneigh Khaldun, MD, MPH, FACEP [Bio]
Chief Deputy Director for Health and CME
[e-mail]

Minnesota
Jan Malcolm [Bio]
Health Commissioner
[e-mail]

Mississippi
Thomas Dobbs, MD, MPH*
State Health Officer
[e-mail]

Missouri
Randall W. Williams, MD, FACOG [Bio]
Director
[e-mail]

Montana
Sheila Hogan
Director
Gregory Holzman, MD [Bio]
Chief Medical Officer
S/THO Designee
[e-mail]

Nebraska
Dannette Smith, MSW *
Chief Executive Officer, Nebraska Department of Health & Human Services
Gary Anthone, MD
Chief Medical Officer and Director, Division of Public Health
S/THO Designee
[e-mail]

Nevada
Lisa Sherych, MBA*
Administrator
[e-mail]

New Hampshire
Lisa Morris, MSSW [Bio]
Director, Division of Public Health Service
[e-mail]

New Jersey
Judith Persichilli RN, BSN, MA*
Commissioner of Health
[e-mail]

New Mexico
Kathy Kunkel, JD, MSW [Bio]
Cabinet Secretary Designee
Abinash Achrekar, MD
Deputy Secretary
S/THO Designee
[e-mail]

New York
Howard Zucker, MD, JD [Bio]
Commissioner of Health
[e-mail]

North Carolina
Mark Benton [Bio]
Assistant Secretary for Public Health
[e-mail]


North Dakota
Mylynn K. Tufte, MBA, MSIM, RN [Bio]
State Health Officer
[e-mail]

Ohio
Amy Acton, MD, MPH [Bio]
Director of Health
[e-mail]

Oklahoma
Gary Cox, JD*
Commissioner of Health
[e-mail]

Oregon
Lillian M. Shirley, BSN, MPH, MPA [Bio]
Public Health Director
[e-mail]

Pennsylvania
Rachel Levine, MD [Bio]
Secretary of Health
[e-mail]

Puerto Rico
Rafael Rodriguez Mercado, MD, FACS, FAANS
Secretary of Health
Catherine De La Cruz-Duran*
S/THO Designee
[e-mail]

Rhode Island
Nicole Alexander-Scott, MD, MPH [Bio]
Director
[e-mail]

South Carolina
Richard Toomey, MHA, DHA [Bio]
Director, South Carolina Department of Health and Environmental Control
[e-mail]

South Dakota
Kim Malsam-Rysdon [Bio]
Secretary
[e-mail]

Tennessee
Lisa Piercey MD, MBA, FAAP [Bio]
Commissioner
[e-mail]

Texas
John Hellerstedt, MD [Bio]
Commissioner
[e-mail]

Utah
Joseph Miner, MD [Bio]
Executive Director
[e-mail]

Vermont
Mark Levine, MD [Bio]
Commissioner of Health 
[e-mail]

Virginia
M. Norman Oliver, MD, MA [Bio]
State Health Commissioner
[e-mail]

Washington
John M. Wiesman, DrPH, MPH [Bio]
Secretary of Health
[e-mail]

West Virginia
Cathy Slemp, MD, MPH [Bio]
Commissioner and State Health Officer
[e-mail]

Wisconsin
Jeanne Ayers, RN, MPH [Bio]
Administrator, Division of Public Health
[e-mail]

Wyoming 
Alexia Harrist, MD, PhD [Bio]
State Health Officer
[e-mail]